INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus
- INO-4800 showed durable antibody and T cell responses in rhesus macaques for 4 months - INO-4800 is the only vaccine to demonstrate long-term protection in non-human primates challenged with SARS-CoV-2 virus 13 weeks from vaccination - Memory T and B cell responses resulted in reduced viral l...
INOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pennsylvania, July 29, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomat...
INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models
- Publication in Nature Communications demonstrates generation of robust neutralizing antibodies and T cell responses against SARS-CoV-2 - Preliminary safety and immune responses data from Phase 1 clinical trial expected in June - Multiple animal challenge study data expected in coming weeks ...
INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo(R) (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment
PLYMOUTH MEETING, Pennsylvania, May 14, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that 85 percent (44 out of 52) of patients newly diagnosed with the deadly brain cancer glioblastoma multiforme (GBM) who received the company's DNA medicine INO-5401, in combination with INO-9012 an...
INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI
INOVIO and Richter-Helm BioLogics will expand existing DNA manufacturing agreement to support large-scale manufacturing of INO-4800 INO-4800 Phase 2/3 U.S. clinical trial being prepared to start this summer PLYMOUTH MEETING, Pennsylvania, April 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today ...
INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference
- INO-4700 (GLS-5300) DNA vaccine demonstrates 100% binding and 92% neutralizing antibody responses against MERS-CoV - INO-4800 DNA vaccine for COVID-19 currently in Phase 1 trial utilizes identical strategy targeting Spike protein and CELLECTRA intradermal delivery PLYMOUTH MEETING, Pennsylvani...
INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June
INO-4800 Phase 2/3 U.S. clinical trial being prepared to start this summer Parallel preclinical challenge studies ongoing PLYMOUTH MEETING, Pa., April 28, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced that its Phase 1 U.S. clinical trial for COVID-19 DNA vaccine INO-4800 is fully enro...
IVI, INOVIO, and KNIH to Partner with CEPI in Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine in South Korea
PLYMOUTH MEETING, Pennsylvania and SEOUL, South Korea, April 16, 2020 /PRNewswire/ -- The International Vaccine Institute (IVI) announced today that the Coalition for Epidemic Preparedness Innovations (CEPI) has granted$6.9 million funding to INOVIO (NASDAQ:INO) to work with IVI and the Korea Nat...
INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
- Up to 40 Healthy Volunteers To Participate at Two Trial Locations - Preclinical Animal Studies Show Promising Immune Responses - Rapid Advancement Possible Through a Global Coalition of Collaborators, Partners, and Funders PLYMOUTH MEETING, Pennsylvania, April 6, 2020 /PRNewswire/ -- INOVIO...
INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia
PLYMOUTH MEETING, Pennsylvania, March 30, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported interim results from an open-label Phase 2 trial designed to evaluate the safety and efficacy of VGX-3100 in women with vulvar dysplasia, also known as high grade squamous int...
INOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia
- VGX-3100 DNA medicine cleared high-risk HPV 16/18-associated precancerous lesions in 50% of patients, and reduced the number of lesions in 75% of patients - Data to be presented at the 2020 American Society for Colposcopy and Cervical Pathology (ASCCP) meeting PLYMOUTH MEETING, Pa., March 26, ...
INOVIO Receives New $5 Million Grant to Accelerate Scale Up of Smart Delivery Device for Its COVID-19 Vaccine
PLYMOUTH MEETING, Pennsylvania, March 12, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has received a new$5 million grant from the Bill & Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRA® 3PSP proprietary smart device for the ...
Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800
Human Trials Planned for April; One Million Doses Expected by Year End PLYMOUTH MEETING, Pennsylvania, March 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19, the respiratory infe...
Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)
- RRP is a rare, potentially fatal orphan disease caused by Human Papillomavirus (HPV) 6 and 11 - Inovio's DNA medicine pipeline includes 15 clinical programs focused on HPV-associated diseases, cancer, and infectious diseases, including the novel coronavirus (2019-nCoV) PLYMOUTH MEETING, Penns...
Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections
PLYMOUTH MEETING, Pennsylvania, Feb. 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced publication of data from its pilot clinical study of INO-3106, a novel DNA therapy targeting human papilloma virus type 6 (HPV 6) for the treatment of recurrent respiratory pap...
Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China
Agreement will facilitate clinical trial translations in China PLYMOUTH MEETING, Pa., Jan. 30, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that it is collaborating with Beijing Advaccine Biotechnology Co. to advance the development inChina of INO-4800, Inovio'...
Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus
PLYMOUTH MEETING, Pa., Jan. 24, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to$9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCo...
Inovio Provides Update on Clinical Program Plans for 2020
Inovio to present 2020 program plans at Biotech Showcase 2020 Conference PLYMOUTH MEETING, Pennsylvania, Jan. 6, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that Inovio's President & CEO, Dr. J. Joseph Kim will present a corporate update of the company's clinical progr...
Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)
80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months PLYMOUTH MEETING, Pennsylvania, Nov. 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today positive interim results from Inovio's Phase 2 study (NCT03491683) of newl...
Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection
PLYMOUTH MEETING, Pennsylvania, Sept. 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that the company and its collaborator The Wistar Institute have received a$4.6 million National Institutes of Health (NIH) grant in support of innovative research to tackle a...
